Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details an increase in notional interests in Ordinary share ADRs for specific individuals following the re-investment of dividends paid on July 7, 2011, at a price of $44.00 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out based on the percentage of deferred annual bonus holdings that vest after the relevant three-year measurement period.
Important Facts for Investors
- Transaction Type: Notification of acquisitions of Ordinary share ADRs under the 2009 Deferred Annual Bonus Plan.
- Participants: Mrs. D P Connelly and Mr. W C Louv.
- Share Price: Transactions occurred at $44.00 per share.
- Dividend Date: Dividends were paid to shareholders on July 7, 2011.
- Regulatory Basis: Filed in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).